Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706998 | 0.91 | CA1 (0.47) | CA1CA2HDAC6L3MBTL1HDAC8 | |
| SCHEMBL1645807 | 0.89 | GSK3B (0.46) | HDAC6L3MBTL1HDAC8HDAC11RAB9A | |
| SCHEMBL7977921 | 0.89 | KDM4E (0.50) | CA1CA2HDAC6L3MBTL1HDAC8 | |
| SCHEMBL25402556 | 0.89 | MRGPRX4 (0.47) | HDAC6RAB9AGAAHDAC1CACNA1G | |
| SCHEMBL7977927 | 0.88 | HDAC6 (0.49) | HDAC6L3MBTL1HDAC8HDAC11SNCA | |
| SCHEMBL25401550 | 0.88 | ALDH1A1 (0.47) | CA1CA2KMT2AADORA3MEN1 | |
| SCHEMBL25403534 | 0.88 | HDAC6 (0.48) | HDAC6RAB9AGAAKMT2AHDAC2 | |
| SCHEMBL25403781 | 0.88 | CACNA1H (0.45) | HDAC6RAB9AGAACACNA1GCACNA1H | |
| SCHEMBL27750270 | 0.87 | KMT2A (0.46) | HDAC6L3MBTL1HDAC8HDAC11RAB9A | |
| SCHEMBL7988907 | 0.86 | THRB (0.50) | HDAC6L3MBTL1HDAC8HDAC11SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4494640-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sookmyung Women's University Industry-Academic Cooperation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212701-A | Novel histone deacetylase heterocycle inhibitor and pharmaceutical composition containing the same | 淑明女子大学校 产学协力团 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023177250-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 숙명여자대학교산학협력단 | 2023-09-21 | — | — | WO | disclosed |
| EP-2298747-B1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| EP-2001480-A2 | INDAZOLE COMPOUNDS | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | CA1 3728/4885CA2 3954/4885HDAC6 90/4885 |
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HDAC1, HDAC6, HDAC5 | CA1 2108/4885CA2 3464/4885HDAC6 2/4885 |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | CA1 835/4885CA2 2750/4885HDAC6 532/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | CA1 3728/4885CA2 3954/4885HDAC6 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.